We are live on ! Find out more
EAM

Eventide Asset Management Portfolio holdings

AUM $6.05B
1-Year Est. Return 76.64%
This Fund
S&P 500
This Quarter Est. Return
+23.31%
1 Year Est. Return
+76.64%
3 Year Est. Return
+247.17%
5 Year Est. Return
+285.6%
10 Year Est. Return
+2,546.71%
AUM
$916M
AUM Growth
+$200M
Cap. Flow
+$82.6M
Cap. Flow %
9.02%
Top 10 Hldgs %
26.61%
Holding
112
New
9
Increased
29
Reduced
6
Closed
6

Top Buys

Rank Stock Value
1
MNDT
Mandiant, Inc. Common Stock
MNDT
+$17.7M
2
TRN icon
Trinity Industries
TRN
+$17.1M
3
SPLK
Splunk Inc
SPLK
+$9.6M
4
NRG icon
NRG Energy
NRG
+$6.27M
5
XPO icon
XPO
XPO
+$6.11M

Top Sells

Rank Stock Value
1
AGIO icon
Agios Pharmaceuticals
AGIO
+$15.5M
2
MDVN
MEDIVATION, INC.
MDVN
+$6.68M
3
AKBA icon
Akebia Therapeutics
AKBA
+$3.68M
4
CBST
CUBIST PHARMACEUTICALS INC
CBST
+$1.92M
5
ARWR icon
Arrowhead Research
ARWR
+$1.69M

Sector Composition

Rank Sector Weight
1 Healthcare 31.22%
2 Technology 16.49%
3 Consumer Discretionary 14.21%
4 Industrials 9.04%
5 Energy 4.42%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NPSP
51
DELISTED
NPS PHARMACEUTICALS INC
NPSP
$8.01M 0.87%
223,900
– –
LGND icon
52
Ligand Pharmaceuticals
LGND
$5.94B
$7.97M 0.87%
239,969
– –
OII icon
53
Oceaneering
OII
$4.74B
$7.63M 0.83%
129,700
+25,800
+25% +$1.66M
CGNX icon
54
Cognex
CGNX
$10.4B
$7.44M 0.81%
360,000
+160,000
+80% +$3.19M
MGNX icon
55
MacroGenics
MGNX
$240M
$7.4M 0.81%
211,000
+20,000
+10% +$499K
OPLN
56
Openlane
OPLN
$4.29B
$7.37M 0.8%
561,689
– –
SGMO
57
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$7.34M 0.8%
482,500
– –
XPO icon
58
XPO
XPO
$23.4B
$6.54M 0.71%
+462,623
New +$6.11M
CMRE icon
59
Costamare
CMRE
$1.87B
$6.34M 0.69%
360,200
– –
FC icon
60
Franklin Covey
FC
$243M
$6.11M 0.67%
315,600
– –
CLDX icon
61
Celldex Therapeutics
CLDX
$3.02B
$5.27M 0.58%
19,247
– –
PWR icon
62
Quanta Services
PWR
$98.7B
$5.19M 0.57%
182,800
– –
SCTY
63
DELISTED
SolarCity Corporation
SCTY
$4.76M 0.52%
89,000
– –
AZPN
64
DELISTED
ASPEN TECHNOLOGY INC
AZPN
$4.5M 0.49%
128,500
– –
AGTC
65
DELISTED
Applied Genetic Technologies Corporation
AGTC
$4.32M 0.47%
205,500
– –
SRPT icon
66
Sarepta Therapeutics
SRPT
$1.64B
$3.75M 0.41%
259,100
– –
CEMP
67
DELISTED
Cempra, Inc.
CEMP
$3.62M 0.39%
153,800
– –
ATRC icon
68
AtriCure
ATRC
$2.04B
$3.04M 0.33%
152,300
– –
TSRO
69
DELISTED
TESARO, Inc.
TSRO
$2.79M 0.3%
+75,000
New +$2.31M
BMRN icon
70
BioMarin Pharmaceuticals
BMRN
$11.7B
$2.73M 0.3%
30,200
– –
NTUS
71
DELISTED
Natus Medical Inc
NTUS
$2.7M 0.3%
75,000
– –
CERN
72
DELISTED
Cerner Corp
CERN
$2.52M 0.27%
38,900
– –
NBIX icon
73
Neurocrine Biosciences
NBIX
$18.7B
$2.51M 0.27%
112,200
+15,600
+16% +$296K
TGTX icon
74
TG Therapeutics
TGTX
$8.19B
$2.46M 0.27%
155,000
– –
XLRN
75
DELISTED
Acceleron Pharma
XLRN
$2.42M 0.26%
62,100
– –
1 2
3
4 5

Similar funds

HPG
Harvest Portfolios Group Oakville, Ontario, Canada $6.06B AUM 16.63% 1-Year Est. Return
EMPI
Elo Mutual Pension Insurance Espoo, Finland $6.06B AUM 24.33% 1-Year Est. Return
RCG
Ruane, Cunniff & Goldfarb New York $6.03B AUM 12.06% 1-Year Est. Return
JWBC
John W. Bristol & Co New York $6.08B AUM 16.51% 1-Year Est. Return
AAM
Advisors Asset Management Monument, Colorado $6.01B AUM 24.74% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return
CM
CastleKnight Management New York $6B AUM 121.87% 1-Year Est. Return
CIS
Capital International Sarl Los Angeles, California $6.11B AUM 32.29% 1-Year Est. Return

Eventide Asset Management's Q4 2014 Portfolio in Review

As of Q4 2014, Eventide Asset Management held 112 positions worth $916M, up 28% from $716M the previous quarter. Its ten largest holdings account for 27% of the portfolio.

Eventide Asset Management deployed $82.6M of net new capital in Q4 2014, opening 9 new positions and adding to 29 existing holdings. Its largest new stake was Mandiant, Inc. Common Stock: 575,600 shares worth $18.2M.

By sector, the portfolio is most concentrated in Healthcare at 31% of assets, up from 29% a quarter earlier, followed by Technology and Consumer Discretionary.

On the sell side, the largest reduction was Agios Pharmaceuticals, an estimated $15.5M trimmed.

  • Eventide Asset Management's largest Q4 2014 buy was Mandiant, Inc. Common Stock: 575,600 shares worth $18.2M.
  • Eventide Asset Management added most to NRG Energy in Q4 2014, an estimated $6.27M increase.
  • Eventide Asset Management's biggest Q4 2014 reduction was Agios Pharmaceuticals, cutting an estimated $15.5M.
  • Eventide Asset Management fully exited Akebia Therapeutics in Q4 2014, selling an estimated $3.68M.
  • Eventide Asset Management's ten largest holdings make up 27% of its $916M portfolio in Q4 2014.
  • Eventide Asset Management opened 9 new positions and closed 6 in Q4 2014.
  • Eventide Asset Management's portfolio value rose 28% quarter-over-quarter to $916M.

Based on Eventide Asset Management's 13F filing for Q4 2014, filed 12 Feb 2015.